In patients with persistent diabetic macular edema (DME), there may be long-term benefits to be gained from continuing with anti-vascular endothelial growth factor (anti-VEGF) therapy, according to a post hoc analysis of a Diabetic Retinopathy Clinical Research (DRCR) Network trial.
Reuters Health Information